SCHEMBL31336075

SCHEMBL31336075

CCNC(=O)C=CCN(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
SLC6A19 Q695T7 1/20 0.36
CHRNB2 P17787 2/20 0.35
CHRNB4 P30926 2/20 0.35
CHRNA3 P32297 2/20 0.35
CHRNA4 P43681 2/20 0.35
ITK Q08881 3/20 0.33
EGFR P00533 3/20 0.33
JAK3 P52333 2/20 0.33
GAA P10253 1/20 0.32
CCNK O75909 1/20 0.32
CDK12 Q9NYV4 1/20 0.32
TAS1R3 Q7RTX0 1/20 0.32
TAS1R1 Q7RTX1 1/20 0.32
MMP1 P03956 1/20 0.31
MMP2 P08253 1/20 0.31
MMP3 P08254 1/20 0.31
MMP9 P14780 1/20 0.31
MMP8 P22894 1/20 0.31
BTK Q06187 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9070554 1.00 ALDH1A1 (0.37) ALDH1A1SLC6A19CHRNB2CHRNB4CHRNA3
SCHEMBL9070664 0.84 ALDH1A1 (0.41) ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL25896074 0.84 ALDH1A1 (0.34) ALDH1A1SLC6A19CHRNB2CHRNB4CHRNA3
SCHEMBL22043583 0.82 CHRNB2 (0.33) ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL23653179 0.82 CHRNB2 (0.38) ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL15951606 0.82 CHRNB2 (0.34) CHRNB2CHRNB4CHRNA3CHRNA4ITK
SCHEMBL12313552 0.81 JAK3 (0.34) CHRNB2CHRNB4CHRNA3CHRNA4JAK3
SCHEMBL14813244 0.80 ALDH1A1 (0.34) ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL12831951 0.80 JAK3 (0.33) ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL14813245 0.80 ALDH1A1 (0.38) ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720038-A1 (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES Neophore Limited (GB) 2026-04-08 EP disclosed
WO-2024246496-A1 (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES Neophore Limited (GB) 2024-12-05 WO disclosed